healthcare

Private Equity

Former J.P. Morgan PE exec joins healthtech specialist Accelmed

Former J.P. Morgan Private Equity executive Katherine Relle has joined Accelmed Partners as vice president. Armed with Masters' degrees from…

Hedge Funds

GordonMD Global Investments launches with licensed physician at the helm

After more than a decade managing global biopharmaceutical portfolios, Dr. Craig Gordon, is striking out on his own with the…

Private Equity

Advent, GIC partner on $8bn deal to take Swedish biotech SOBI private

Advent International and Aurora Investment, a subsidiary of Singapore sovereign wealth fund GIC, have offered to buy all shares of…

Private Equity

CDPQ, Centerbridge buy Medical Solutions for piece of $20 billion-plus U.S. healthcare staffing market

Caisse de dépôt et placement du Québec (CDPQ) and funds advised by Centerbridge Partners entered into a definitive agreement to…

Manager News

NovaQuest’s Azurity Pharma acquires Arbor Pharma from KKR, others

Azurity Pharmaceuticals entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors, including JW Asset Management and KKR.…

Private Credit

Deerfield unveils $1.4bn healthcare finance fund

Deerfield Management Company launched Deerfield Private Design Fund V, closing at $1.4 billion in committed capital. The firm, which is…

Private Credit

SLR seeks $800m for healthcare private debt fund

SLR Capital Partners raised an initial $480 million in equity commitments for its healthcare direct lending funds that along with…

Featured

PAAMCO co-founder Jane Buchan joins Immix Biopharma board

Dr. Jane Buchan added another feather to her cap on Wednesday by joining the Immix Biopharma board of directors. Buchan…

Investor News

NEPC: U.S. healthcare institutions optimistic on investments

Consulting firm NEPC released the results of its 2021 Healthcare Operating Survey that revealed the industry’s positive views on investing.…

Private Equity

Blackstone commits $250m to back new CAR T-cell therapies

Blackstone Life Sciences is investing $250 million toward developing CAR T-cell therapies for immuno-oncology and autoimmune diseases, forming a new…

Back to top button